Better treatments...
Better lives.

ALLG News

Edition 8

Message from the CEO	2
ALLG Consumer Representative Panel	3
Impactful Trials – Chronic Lymphocytic Leukaemia (CLL)	4
ALLG's CLL Leaders	5
ALLG – Accelerating Impact	6
Members on the International Stage	8
South Australia Chronic Myeloid Leukaemia (CML) Research Teams	10
Supporting ALLG / TEAM ALLG	12
Fundraise for Us / Ways to Support	13
Patient and Carer Resources	14

Australasian Leukaemia and Lymphoma Group (ALLG)

Better Treatments, Better Lives; Aiming for cure

Read past editions
of ALLG News

Follow ALLG on Facebook, X and Linkedin

Message from CEO

Welcome from ALLG Chief Executive Officer

Welcome to the eighth edition of ALLG News. Here, you can read about how we continue to work towards a cure for blood cancer through innovative clinical trial research, the work of our Consumer Representative Panel and their impact on our research, the leaders behind the scenes responsible for our clinical trials, and much more.

It's been an exciting few months at ALLG, with the release of our ***2023 Research Report*** and our successful ALLG May Scientific Meeting, which took place in Adelaide.

Our Scientific Meetings are important biannual events that bring together our member clinicians to discuss new ideas for clinical trial research and provide the opportunity to keep pace with a rapidly evolving field. Over the meeting week, it was inspiring to see our members engage in the presentations and sessions as we work collaboratively to generate and share new research concepts to drive better blood cancer treatments.

Virtually every cancer treatment available to people with cancer today is the direct result of a clinical trial. Our clinical trial research is only made possible through the generosity of people participating in ALLG clinical trials. To further this link, ALLG and Leukaemia Foundation co-hosted a Patient Education and Engagement Forum at our recent Scientific Meeting for patients with chronic myeloid leukaemia (CML).

During this forum, CML patients and carers had the opportunity to hear from Associate Professor David Yeung about what's on the horizon for CML treatments, including ALLG's new CML14 ASCENDANCE clinical trial. During the CML forum a participant of the ALLG CML11 trial shared their experience of being diagnosed with CML and their participation in the CML11 trial, which has subsequently led to remission!

Patients sharing their lived cancer experiences is vital to the design and conduct of ALLG clinical trials, with the ultimate goal of improving treatments. Our Consumer Representative Panel (CRP) plays an important role in ALLG's clinical trial process. They provide input and insights to our researchers about their own experience of living through, and surviving blood cancer. These insights are invaluable when it comes to the trial design and delivery processes.

The CRP also provides the important 'patient voice' to the clinical research process, ensuring that ALLG trials consider and incorporate a patient-first focus. Our patients are the heart of everything we do at ALLG, and we are grateful for every patient that participates in our clinical trials as we work towards the shared mission of *Better treatments, Better lives*, and a potential cure for blood cancers.

In this ALLG News, you can also read about our progress in Chronic Lymphocytic Leukaemia (CLL) clinical trials, including the new CLL08 trial. Opening soon CLL08 is trialling a promising combination treatment for patients whose CLL has progressed/ relapsed after current standard therapies.

Finally, we released our latest ***Research Report*** in May. The 2023 report provides a comprehensive overview of ALLG clinical trials across all areas of blood cancer and progress, milestones and results.

The Research Report showcases our dedication and success in delivering cutting-edge treatments to patients with leukaemia, lymphoma, myeloma and other blood cancers, across Australia and New Zealand.

I hope you enjoy this edition of ALLG News.

Yours Sincerely,

Delaine Smith
Chief Executive Officer
ALLG

To read a comprehensive overview of ALLG's clinical trials click here.

ALLG Consumer Representative Panel

Patients are our focus at ALLG, and their feedback about their blood cancer journey is an essential part of how our members develop and conduct clinical trials. Engagement with our Consumer Representative Panel has been an active part of the trial process since the year 2000, through their assistance with patient-centred summary reviews of our clinical trials, trial participant information, and input on our grant funding applications.

The involvement and perspective of our Consumer Representative Panel is essential, and we deeply appreciate their contributions to further our mission of *Better treatments, Better lives.*

If you're interested in learning more about our Consumer Representative Panel or becoming a member, we invite you to find out more information at ***allg.org.au***

Anne Hodgson Acute Myeloid Leukaemia Survivor

"The drugs and protocols offered to patients during clinical trials come at no cost and participation in trials for some patients may give them opportunities and hope, that may not have been accessible otherwise. Participation in a Clinical Trial also means regular and careful attention from Health Professionals in addition to the care offered by your own Specialist."

Steve Towell Mantle Cell Lymphoma Survivor

"Life is good, and I am living it, but now I feel like I need to give something back. I've been doing some fundraising and a little public speaking, which has led me into ALLG as a Consumer Representative. I am hoping I can do some more good work and help others to get through it a little easier than I did. Clinical trials are the only way we get new and better treatments. That's what the ALLG is all about."

Pam K Acute Myeloid Leukaemia Survivor

"If I had acute myeloid leukaemia (AML) 30 years earlier it would have been a death sentence, but research has made survival not only possible but has improved survivors' quality of life. Hopefully in another 30 years' time a blood cancer diagnosis will just be a minor inconvenience."

John Stubbs AM Chronic Myeloid Leukaemia Survivor

"On 1 March 2001 I underwent a Bone Marrow Transplant. As a former cancer patient who underwent a clinical trial, I now see it as my job to promote, engage and encourage access to cancer research and clinical trials."

Emma Priest Hodgkin Lymphoma Survivor

"Research is so important to continue to improve treatments for diseases and conditions so that we can either eradicate them or manage them effectively for improved quality of life."

Chris Kershaw Non Hodgkin Lymphoma Survivor

"After being told I had a tumour in my pelvic bone and after reviewing the trial information, I was placed in the care of Prof Hertzberg and all the wonderful nursing professionals at POW. I had an exceptional experience on the trial and have remained in remission ever since. I have just recently joined the CRP to help make a difference by sharing my journey and experience."

You can ***read their full stories and experiences of clinical trials here*** to gain an insight into the impact of their blood cancer experience and what survivorship means to them.

We hope these stories and our work offer encouragement and support to patients and their families suffering from blood cancer.

Impactful Trials – Chronic Lymphocytic Leukaemia (CLL)

In 1989,
less than half (49%)
of persons over 80 years old diagnosed with CLL
survived 5 years
after diagnosis.

Three decades later,
two thirds (66%)
of persons over 80 years old diagnosed with CLL
survived 5 years
after diagnosis.

Chronic Lymphocytic Leukaemia, or CLL, is the most common form of leukaemia in Australia and New Zealand. CLL is a cancer of the blood and bone marrow, specifically the B-Cell lymphocytes, that usually progresses slowly and often occurs during or after middle age. CLL is generally incurable, and patients will live with it for the rest of their lives. Many people can live a full life without symptoms and never need treatment. Others will experience symptoms at some stage and need treatment, with the goal of treatment putting their CLL into remission.

CLL treatments have vastly improved over the last twenty years, with targeted therapies such as venetoclax, ibrutinib and rituximab becoming the new standard of care for CLL. Many different drugs and drug combinations can be used as the first treatment to improve overall survival rates.

Currently, there is no cure for CLL, but many patients experience long and lasting remission from their cancer with standard treatments. For those who don't, there are other options such as stem cell transplant and approaches that tailor the duration of treatment using a combination of targeted therapies such as those in our new CLL08 clinical trial.

International CLL Partnerships

ALLG continues to strengthen its partnerships with international CLL groups across the globe to bring new, cutting-edge treatments to patients across Australia and New Zealand. Collaborating internationally also enables ALLG researchers to contribute to larger, global clinical trials that help power innovative treatments with the aim of finding a cure.

New Trial Collaborations - Europe

ALLG is collaborating with leading CLL research group, the German CLL Study Group (GCLLSC), on a new phase 3 trial that is comparing standard of care R-CHOP chemotherapy with a new bispecific antibody called epcoritamab in CLL patients with Richters Transformation.

We are also working with the HOVON CLL group in the Netherlands to bring a new clinical trial to Australia and New Zealand called CLL12 AETHER, which will use new exciting immunotherapy combinations for patients with relapsed CLL.

These research collaborations have been a major focus of our CLL Scientific Working Party and international meetings over the last 12 months.

CLL08 Trial

Despite advances in CLL treatment and management, it remains an incurable cancer. Developing new, effective drug combinations is important to provide further treatment options for patients with relapsed CLL.

Led by Chief Investigator A/Prof Mary Ann Anderson and Co-Investigator Dr Kah-Lok Chan, the ALLG CLL08 trial is a phase II clinical trial that aims to determine if re-treating CLL patients with a combination of venetoclax and rituximab after relapse and previous venetoclax therapy is effective in prolonging disease remission. CLL08 will open in late 2024 and be available to up to 80 patients across Australia and New Zealand.

ALLG's CLL Leaders

ALLG's clinician-researchers in CLL are led by our Scientific Working Party Co-Chairs, Professor Stephen Opat and Associate Professor Mary Ann Anderson. Prof Opat and A/Prof Anderson, and Dr Phillip Thompson, a member of the ALLG CLL Scientific Working Party, are leading the development of new research ideas, international collaborations and clinical trials with the aim to deliver better treatments for patients with CLL.



Professor Stephen Opat
Co-Chair CLL Scientific Working Party

Prof Stephen Opat is Co-Chair of the ALLG CLL Scientific Working Party. He is also the founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship. He trained in Haematology at The Alfred and Austin Hospitals in Melbourne followed by a fellowship in Cambridge UK, researching Hodgkin lymphoma biology.

He is a Clinical Professor in the School of Clinical Sciences at Monash University and a principal investigator in over 60 trials mainly in lymphoid cancer. His interests include the clinical management of lymphoma and chronic lymphocytic leukaemia, lymphoma genomics and Gaucher disease.

Associate Professor Mary Ann Anderson
Co-Chair CLL Scientific Working Party

A/Prof Mary Ann Anderson is Co-Chair of the ALLG CLL Scientific Working Party, and a clinician scientist who focuses on new treatments for leukaemia and lymphoma. She studies potential anti-cancer agents that target proteins to keep cancer cells alive with the long-term goal of developing better treatments for people with cancer, without the serious side effects of chemotherapy.

Together with a wider team from her research institute, the Walter and Eliza Hall Institute (WEHI), Mary Ann's work has pioneered the development of the drug venetoclax for the treatment of leukaemia and lymphoma. Her current research focus is understanding why some patients do not respond as well or develop resistance to venetoclax. By identifying the reasons for ventoclax resistance she aims to develop new techniques and treatment combinations to prevent this occurring, and to facilitate better disease control and prolonged survival for patients.

Dr Philip Thompson
CLL Scientific Working Party Member

Dr Philip Thompson is a member of the ALLG CLL Scientific Working Party and Associate Professor of Haematology in the Sir Peter MacCallum Department of Oncology, University of Melbourne. He is also a Clinical Haematologist at Peter MacCallum Cancer Centre and Royal Melbourne Hospital.

After graduating from The University of Melbourne and completing Residency and Haematology training in Melbourne, he undertook a Leukemia Fellowship at the prestigious M.D. Anderson Cancer Center in Texas, before joining the Faculty at M.D. Anderson from 2015-2023. There, he described the functional cure of patients with low-risk CLL after Fludarabine, cyclophosphamide and rituximab (FCR) and developed research interests in the treatment of high-risk CLL and Richter Transformation, and the development MRD-adapted treatment approaches.

Dr Thompson has led several clinical trials in these areas and is currently working on several international CLL trial collaborations.

ALLG – Accelerating Impact

With a remarkable 5 decades of impact, ALLG continues to accelerate our research to drive new treatments and find new ways to transform blood cancers into potentially curable diseases. With over 75 clinical trials in progress, our National Blood Cancer Registry (NBCR) driving new discoveries, and recent breakthroughs in precision medicine, immunotherapies and CAR-T cell therapies, we are collectively working towards better treatments that improve survival, quality of life, and ultimately a cure.

We are dedicated to ensuring the sustainability of our research, implementing a range of ALLG programs to power new research and discoveries, and develop the next generation of blood cancer researchers driving our mission forward.

Accelerating Research

Our ALLG Research Report 2023 contains comprehensive information about our blood cancer clinical trial portfolio, milestones, and progress during this year, along with reports from our key researchers and scientific leaders, including the ALLG Scientific Advisory Committee, Standing Member Committees, and Scientific Working Parties.

Read more at ***allg.org.au***

Accelerating the Impact
ALLG HSANZ Clinical Trials Fellowship

ALLG's 50th anniversary celebrations in 2023 provided the perfect opportunity to establish the ALLG HSANZ Clinical Trials Fellowship, and helped mark this momentous ALLG milestone. Through the support of our ALLG members, donors and community, we were able to launch the Fellowship program in early 2024.

The ALLG Fellowship will provide outstanding early-career researchers with a pathway to accelerate research for better, less toxic treatments that help create better lives and improve patient survival outcomes.

To find out more about the ALLG HSANZ Clinical Trials Fellowship, or to support this vital program, visit:

www.allg.org.au/support-us/our-campaigns

ALLG National Blood Cancer Registry & ALLG Biobank

ALLG's National Blood Cancer Registry (NBCR) is a registry that details the clinical pathways of patients suffering from blood cancer to help create better treatments and better lives for patients.

The National Blood Cancer Registry (NBCR) and Biobank now have over 4,400 participants, providing researchers with access to blood and tissue samples.

If you're interested in volunteering for this important research infrastructure that's helping make new discoveries for patients with Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukaemia (ALL), Myelodysplasia (MDS), and uncommon lymphomas, talk to your doctor who can explain the process of becoming an NBCR participant.

Accelerating the Impact - ALLG Early Career Clinician Researcher Program (ECCR)

ALLG remains steadfast in its commitment to advancing blood cancer research and progressing world-leading clinical trials. As part of this commitment, we are proud to offer the Early Career Clinician Researcher Program - a unique opportunity for trainees, registrars, fellows, and junior consultants to further their pursuit of cancer and haematology research, and contribute to the future of our research field.

The ECCR Program includes opportunities for early career clinician researchers to:

- Generate ALLG Member research
- Develop ideas for clinical or laboratory-based research
- Network with other health professionals, including other ALLG early career members, in the blood cancer research community
- Receive mentoring by ALLG Scientific Advisory Committee leaders in the development and conduct of clinical trials

ECCR Program Participants

ALLG would like to celebrate our two inaugural Early Career Clinician Researchers on their completion of the program. Congratulations to Dr Katharine Lewis and Dr Georgia McCaughan on their efforts and achievements.

Dr Katharine Lewis
Co-Chief Investigator on ALLG NHL35 PACIFIC trial in Lymphoma

Dr Georgia McCaughan
Co-Chief Investigator on ALLG's MM26 NORM platform clinical trial in Myeloma

ALLG 2024-2025 Early Career Clinician Researchers

ALLG also congratulates our new intake of Early Career Clinician Researchers for 2024/2025.

Dr Ross Salvaris
Monash Health, Melbourne

Dr Jacinta Perram
St Vincent's Hospital, Sydney

Dr Rory Bennett
North Shore Hospital, Auckland

We look forward to working with them all to advance clinical trial research for blood cancer patients.

ALLG Members on the International Stage

European Hematology Association 2024 Meeting

Our members are the driving force behind ALLG's clinical trials, and they represent our organisation at the most significant blood cancer meetings worldwide. Recently, three ALLG members had trial abstract presentations accepted at the European Hematology Association (EHA) 2024 Meeting in Madrid, Spain, from 13 - 16 June.

EHA is the largest Europe-based organisation connecting haematologists globally to support excellence in patient care, research and education to work towards preventative blood cancer measures, improved quality of life and potentially a cure. The EHA collaborates with international medical associations, national societies and organisations worldwide, and consists of haematologists, researchers, patients, geneticists, nurses, and other medical professionals.

The opportunity for our members to present at this significant annual event highlights the importance and global reach of our ALLG clinical trial research.

A major highlight was Associate Professor Matthew Greenwood presenting the ALLG ALL09 SUBLIME trial in a prestigious invited presentation. ALL09 is a clinical trial aimed at finding a better way to treat adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL).

This disease is the most common form of childhood cancer, with over 80% of children cured with chemotherapy. Adolescents and adults with ALL unfortunately have worse overall survival outcomes. ALL09 was designed to assess whether the introduction of a potent immunotherapy drug, blinatumomab, would improve outcomes in newly diagnosed ALL in these patients.

The ALL09 trial final results showed that substituting blinatumomab for standard chemotherapy treatment resulted in a much higher rate of disease remission, paving the way for adoption of this new treatment regime for AYA ALL patients.

ALL09

A/Prof Matthew Greenwood

Oral Presentation

Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL – Final results of the ALL ALL09 'Sublime" study

Other ALLG members who had posters accepted at EHA were:

MDS05/D1

A/Prof Anoop Enjeti

Poster Presentation

ES-3000, A WNT/ B Catenin / Inflammasome pathway inhibitor combined with oral Decitabine / Dedazuridine (ASTX727) for patients with Myelodysplasia.

GHSG HD21 / ALLG HD10

Prof Mark Hertzberg

Oral Presentation

By international Chief Investigator of the HD21/HD10 trial, Prof Peter Borchmann. The randomized study GHSG HD21 shows superior tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma.

ALLG congratulates Associate Professor Matthew Greenwood, Associate Professor Anoop Enjeti and Professor Mark Hertzberg for their contributions to blood cancer research.

ALLG Members at EHA

ALL09 A/Prof Matthew Greenwood

A/Prof Anoop Enjeti & Dr Ing Soo Tiong

HD10 Presentation

ALLG & HOVON Meeting (L-R): A/Prof Matthew Greenwood, A/Prof Anoop Enjeti, Dr Marleen de Ridder, Delaine Smith, Prof Arnon Kater, Prof Stephen Opat & Prof Zoe McQuilten



Pictured Left To Right – Prof Sue Branford, A/Prof David Ross, Prof Tim Hughes, A/Prof David Yeung & Prof Deborah White

ALLG's May 2024 Scientific Meeting

ALLG's May 2024 Scientific Meeting was a great success. ALLG members from across Australia and New Zealand gathered to discuss clinical trial advancements and to share new and innovative blood cancer research that may increase survival rates and provide a better quality of life for patients.

This Scientific Meeting saw delegates come together for the first time for a trial poster viewing event. This enabled ALLG members to view all ALLG trial abstract posters and presentations from prestigious local and international conferences over the last 12 months, including ICML23, Blood23 and ASH23. This event showcased the breadth and depth of our collective achievements and demonstrated the impact ALLG trials are having through pioneering better treatments for patients.

South Australia Chronic Myeloid Leukaemia (CML) Research Teams

At our ALLG Scientific Meeting we also celebrated a group with significant global achievements, with some of our ALLG Hall of Fame-winning members from the South Australia Chronic Myeloid Leukaemia (CML) Research Teams engaging in a fascinating panel discussion on clinical and laboratory teams working together for success.

Facilitated by CML Scientific Working Party Chair, Dr Courtney Tate, the panel discussed how over three decades the team at Royal Adelaide Hospital Haematology and Clinical Trials Unit, the CML research team of South Australia Health Medical Research Institute (SAHMRI), and the University of South Australia have driven significant change and discovery in the field of CML. Their efforts were linked and leveraged through the ALLG clinical trial program for the advancement of molecular testing, meaning treatment for CML has accelerated with world-wide impact for patients.

We thank Prof Tim Hughes, Prof Deborah White, Prof Sue Branford, A/Prof David Ross and A/Prof David Yeung, along with Dr Courtney Tate, for their input into this engaging discussion and insights into their team's success.

SA CML Research Teams' Achievements

- 1342 patients have benefited from participation in ALLG trials
- 20+ publications have been released on the treatment outcomes and correlative research projects
- Survival rates of patients with CML in the past 20 years have drastically increased, from fatal within years to life expectancy the same as other people their age
- Access to therapy has been transformed from intensive hospital care to outpatient care with easy-to-use tablet treatments
- The team's correlative research outcomes have contributed to the optimised use of a targeted type of therapy, Tyrosine kinase inhibitors (TKIs), and set guidelines and standards locally and internationally

Members at ALLG's May 2024 Scientific Meeting

Prof Stephen Opat, CLL SWP Co-Chair

Prof Mark Hertzberg, ALLG Life Member & HD10 Chief Investigator with Julia Carlson, Project Manager - Lymphoma & Myeloma Trials

ALLG Members Networking

ALLG Members Networking

Prof Judith Trotman, Scientific Advisory Committee Chair

Supporting ALLG

ALLG has been making an impact for patients with blood cancer for over five decades, through our world-leading clinical trial research that creates better treatments and better lives.

But we need to do more.

Every year, nearly 20,000 Australians and 2,000 New Zealanders will be diagnosed with a blood cancer like leukaemia, lymphoma or myeloma. Blood cancer can develop in anyone, at any age, at any time and there are no preventative measures available like there are for other cancers.

We need your support to help fund our essential blood cancer research. You can support ALLG in many different ways and every single donation helps to make a difference.

www.allg.org.au/support-us

Team ALLG

Looking to put the FUN back into fundraising? Why not join Team ALLG and become part of the movement that inspires each other to help support and combat blood cancer.

You can run, cycle, swim or take on another challenge to raise funds for blood cancer research. You can join an existing event, like Run Melbourne or City 2 Surf, or get together with friends and workmates to create your own challenge.

By joining Team ALLG, you get to support a great cause, keep fit, and make a difference for blood cancer patients.

Together, we can change the future for patients with leukaemia, lymphoma and myeloma.

Find out more about...

TEAM ALLG

Upcoming challenge events

Find out more about team ALLG and the upcoming challenges by clinking on the events listed below:

Run Melbourne 2024
21 July 2024

City 2 Surf 2024
11 August 2024

Bridge to Brisbane 2024
8 September 2024

Sydney Marathon 2024
15 September 2024

Perth Running Festival 2024
6 October 2024

Melbourne Marathon 2024
13 October 2024

Fundraise for Us

Fundraisers are vital to ALLG's work and there are so many fun ways to get involved and help the ALLG make a difference for blood cancer patients.

You can be as creative as you like with your fundraising – from hosting a morning tea at work to running a sausage sizzle, or a trivia night to a golf charity day, to whatever you can imagine – the sky is the limit!

By fundraising for ALLG, you will be directly helping our members to advance clinical trial research and tackle the biggest challenges of blood cancers.

Learn more about ways **you can fundraise** for better treatments, better lives: ***https://www.allg.org.au/support-us/fundraise-for-us/***

Ways to Support ALLG

You can support ALLG in many different ways. For more information, click on the links below or visit ***allg.org.au***

The Australasian Leukaemia and Lymphoma Group is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations over $2 are tax-deductable.

Patient and Carer Resources

As the only non-profit collaborative clinical trials group in Australia and New Zealand for blood cancers, ALLG has the capability to run independent doctor-led clinical trials in Australasia and, crucially, to participate in international trials. This ensures opportunities for better treatments today for Australian and New Zealand patients that they would not otherwise have access to. You can learn more about clinical trials and what they involve, by visiting our website's ***Frequently Asked Questions*** page. If you are a loved one has blood cancer, speak with the treating doctor about participating in an ALLG clinical trial.

There are many places and people available for patients to find out about clinical trials.

1. Your hospital's clinical trial site team and Principal Investigator (Haematologist)
2. The ALLG's website – as sponsor of clinical trials in blood cancer (ALLG or pharmaceutical company) and individual trial Patient Information and Consent Forms
3. WHO approved 'Register' for clinical trials; Australian Clinical Trials website – ANZCTR
4. Patient support networks e.g. Cancer Council Australia, Leukaemia Foundation, Lymphoma Australia, Myeloma Australia

Click on the logos and titles to link to websites

ALLG
– Frequently Asked Questions about clinical trials
– Latest ALLG clinical trials

Australia and New Zealand Clinical Trials (ANZCTR)

Leukaemia Foundation Australia

Leukaemia & Blood Cancer New Zealand

Lymphoma Australia

Myeloma Australia

If you would like to read past editions of ***ALLG News***, visit the ALLG website.

You can also follow us for more news on ***Facebook***, ***X*** and ***Linkedin***.

© 2024 Australasian Leukaemia and Lymphoma Group
Ground Floor, 35 Elizabeth Street, Richmond VIC 3121
www.allg.org.au